Abstract: Neonates at risk of childhood atopy and asthma are characterized by gut microbiome 15 perturbation and fecal enrichment of 12,13 DiHOME(1); however, the underlying mechanism and source of this metabolite remain poorly understood. Here we show that 12,13 DiHOME treatment of human dendritic cells altered peroxisome proliferator-activated receptor γ regulated gene expression and decreased immune tolerance. In mice, 12,13 DiHOME treatment prior to airway challenge exacerbated pulmonary inflammation and decreased lung regulatory T cells. 20 Neonatal fecal metagenomic sequencing revealed putative bacterial sources of 12,13 DiHOME. In our cohort, three bacterial genes and their product, 12,13 DiHOME, are associated with increased odds of childhood atopy or asthma, suggesting that early-life gut-microbiome risk factors may shape immune tolerance and identify high-risk neonates years in advance of clinical symptoms.
altered the distribution of CD4+ T cells, specifically by decreasing the frequency of Tregs without decreasing cell viability (Fig. 1b-c, Fig. S1b-c ).
To evaluate whether 12,13 DiHOME exerts this effect via PPARγ, we isolated RNA from human DCs treated with 12,13 DiHOME and examined the expression of PPARγ-regulated genes. 12,13 DiHOME treatment mimicked previously characterized effects of PPARγ 5 activation: decreased expression of CD1a, an immune marker involved in lipid presentation (7) ; increased expression of CD36, a fatty-acid transporter implicated in 12,13 DiHOME-regulation of brown adipocytes (8) ; and increased expression of FABP4 and HADH, genes involved in fatty acid uptake and metabolism (7) (Fig. 1d-e) . To confirm these observations, we used flow cytometry to examine the effects of 12,13 DiHOME on the expression of PPARγ-regulated 10 proteins in human DCs. Again, 12,13 DiHOME treatment mimicked PPARγ activation, increasing expression of CD36, and decreasing expression of CD1a, CD80, and CCR7, immune markers involved in lipid presentation, antigen presentation, and cell trafficking (7) , in human DCs (Fig. 1f-i, Fig. S1f-g ). To test whether 12,13 DiHOME directly acts on PPARγ, we utilized a modified PPARγ reporter assay (9) and demonstrated that treatment with concentrations of 15 12,13 DiHOME in excess of 50 μM leads to PPARγ activation (Fig. 1j) . While PPARγ activation in DCs is traditionally considered anti-inflammatory (10, 11) , recent studies suggest that PPARγ may in fact promote allergic inflammation (12) . Alternatively, 12,13 DiHOME may act as a weak agonist of PPARγ and compete with endogenous PPARγ ligands found in serum (13) .
20
We next examined whether 12,13 DiHOME exacerbates allergic sensitization in vivo, by treating mice with 12,13 DiHOME (30 mg/kg) or vehicle (10% DMSO) via peritoneal injection prior to airway sensitization and challenge with cockroach antigen (CRA) (14) . Treated animals exhibit increased peribronchial and perivascular inflammatory infiltrates and serum IgE compared to those treated with vehicle alone (Fig. 2a-d, Fig. S2a-b) . 12,13 DiHOME-treated 25 animals also exhibited increases in lung resident T cells, neutrophils, and monocytes, and pulmonary expression of pro-inflammatory innate cytokines, IL1β, IL1α, and TNF, as well as a significant decrease in the frequency of lung Tregs and a trend towards decreased lung resident alveolar macrophages (Fig. 2e-g, Fig. S2g-k) . These inflammatory immunologic changes may be explained by the effect of 12,13 DiHOME on PPARγ observed ex vivo. Alternatively, 12,13 30 DiHOME was recently identified as an activator of transient receptor potential vanilloid 1 (TRPVI) (15) , loss of which is associated with decreased asthma prevalence in humans and protection against airway inflammation in animal models (16, 17) . To evaluate whether oxylipins delivered in the peritoneum reach the circulation, we quantified 12,13 DiHOME by liquid-chromatography mass spectrometry (LC-MS) (18) three hours after injection and observed 35 significant enrichment in both the plasma and lungs when compared with vehicle-treated animals (Fig. 2h, Fig. S2l ), indicating that 12,13 DiHOME may interact directly with lung tissue to exacerbate allergic airway inflammation.
Given the apparent role of this lipid in driving pro-allergic immune dysfunction in mice and humans, we focused on determining the concentration and potential sources of 12,13 40 DiHOME in neonatal feces. We began by quantifying 12,13 DiHOME and 9,10 DiHOME (its enantiomer and a known agonist of PPARγ (19)) using LC-MS in a subset of one-month-old neonates from the Wayne County Health, Environment, Allergy & Asthma Longitudinal Study (WHEALS; Table 1 ; total n=41; atopic=7; asthmatic=8; atopic asthmatic=4) (1) . These included 26 one-month old stool samples that had been previously selected for untargeted metabolomic profiling based on their representation of the varied gut microbiome composition observed across 130 one-month old subjects (1) , and an additional 15 randomly selected one-month old samples that had more than 50 mg of stool and 10 ng of extracted fecal DNA remaining, and had childhood atopy and/or asthma outcomes available. 12,13 DiHOME was present in all neonatal stool, but was detected at significantly higher concentrations in the stool of neonates who 5 subsequently developed atopy and/or asthma (Fig. 3a) . In contrast the concentration of 9,10 DiHOME did not significantly differ between the two groups (Fig. S3a) .
12,13 DiHOME is a terminal metabolic product of linoleic acid, which is initially converted to 12,13 EpOME either enzymatically via a cytochrome P450 epoxygenase (20) or spontaneously via oxidation; 12,13 EpOME is then converted to 12,13 DiHOME via an epoxide 10 hydrolase (EH); an enzyme encoded by humans, bacteria and fungi (21) (22) (23) . To identify potential sources of 12,13 DiHOME, the aforementioned 26 neonatal stool samples (1) underwent shotgun metagenomic sequencing. A database of known bacterial (~73,000), fungal (~5,000), and human (~50) EH genes was assembled and used in conjunction with ShortBred (24) to probe the neonatal metagenomic data for sequence reads with EH homology. No fungal or human EH 15 genes were detected; however, approximately 1,400 bacterial EH genes were identified. Bacterial EH genes were significantly more abundant in the stool of neonates who developed atopy and/or asthma (Fig. 3b) . The thirty most abundant of which were primarily encoded by Enterococcus faecalis, Streptococcus, Bifidobacterium bifidum, and Lactobacillus strains (Fig. 3c ).
To evaluate whether these putative EH genes are capable of hydrolyzing epoxides and 20 producing 12,13 DiHOME, a cell-based assay was developed. A subset (n=11) of the most frequently detected putative bacterial EH genes, with ≥75% of homologous EH marker regions identified in the metagenomic data, were selected (Table S1 ). These genes were synthesized and cloned into Escherichia coli for expression. EH activity was measured using modifications of a previously described colorimetric assay (25) . All 11 genes are capable of hydrolyzing glycidol, a 25 generic epoxide, to its conjugate diol, glycerol, and three can hydrolyze 9,10 EpOME to 9,10 DiHOME. However, only NP_814872 (E. faecalis), YP_003971091 (B. bifidum), and YP_003971333 (B. bifidum) can convert 12,13 EpOME into 12,13 DiHOME (Fig. 3d) , indicating that while EH activity is common, the specific capacity to produce 9,10 or 12,13 DiHOME may be bacterial strain specific.
30
To test whether the three 12,13 DiHOME-producing bacterial EH genes (3EH) were sufficient to distinguish neonates who developed atopy and/or asthma in childhood from those who did not, we developed qPCR assays to quantify the 3EH copy number in neonatal stool. We measured fecal 3EH copy number in our subset of the WHEALS cohort and observed a significant increase in the stool of neonates who subsequently developed atopy and/or asthma in 35 childhood (Fig. 3e) . Armed with these data we evaluated whether fecal 12,13 DiHOME and 3EH copy number were associated with increased odds of childhood atopy or asthma. Using our subset of the WHEALS cohort (n=41, Table 1 ) and univariate logistical regression, we examined the odds of developing atopy at age two years or asthma at age four years based on neonatal fecal 12,13 DiHOME concentration, fecal 3EH copy number, or known early-life risk factors selected a priori based on previously published literature. These included male gender; race; maternal asthma; lack of pets, maternal smoking, and environmental smoke exposure pre-delivery; delivery by Cesarean section; and formula feeding at one month (26-32).
Univariate modeling indicated a significant increase in the odds of atopy at age two years with increased fecal 3EH, and a significant increase in the odds of asthma at age four years with an increased fecal concentration of 12,13 DiHOME at one month (Figure 3f ,g, Table S6 ,7). Multivariate modeling was used to test the remaining risk factors for potential confounding. There was no strong evidence for confounding in the relationship between 3EH copy number and 5 the development of atopy at age two (all changes in odds ratio < 20%); however, when we examined the relationship between fecal 12,13 DiHOME concentration and the development of asthma at age four, race was identified as a potential confounder. We adjusted for race in our model and found that 12,13 DiHOME concentration remained significantly associated with asthma development at age four (Table S7 ). Clearly these neonatal gut microbiome risk factors 10 require validation in additional larger cohorts. Nonetheless they offer potential for early life identification of those at risk for atopy and asthma years in advance of clinical symptoms, when prevention is most likely to be effective.
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Metagenomic data generated in this study is available in the EMBLI repository Accession # PRJEB24006 (https://www.ebi.ac.uk/). Additional datasets and materials are available from the corresponding author upon request. Data sets and R scripts used for statistical analysis and figures are available on GitHub (https://github.com/srlevan/). HADH, respectively). (F,G,H,I) 12,13 DiHOME increases the expression of CD36 at high concentrations (LME; p=0.0225 for 200 µM) and decreases the expression of CD1a, CD80, and CCR7 on DCs (CD3-CD19-CD11c+; LME; p<0.001 for all comparisons CRA-challenged (n=16; LME; p=0.105) and PBS-challenged animals (n=10; LME; p=0.0022). (C,D) 12,13 DiHOME treatment (n=14) increases the number of infiltrating cells surrounding the bronchioles and veins of CRA-challenged mice compared with vehicle treated, PBS challenged [n=5; LME; p=0.00263 (bronchial), p=0.00087 (venous)] or vehicle treated, CRA challenged [n=13; LME; p=0.0298 (bronchial), p=0.0107 (venous)] animals. (E) Peritoneal 12,13 DiHOME 10 treatment increases the frequency of lung resident T cells (CD3+) in CRA challenged mice (n=9) compared with vehicle treated, PBS challenged (n=10; LME; p=4.69x10 -6 ) or vehicle treated, CRA challenged (n=10; LME; p=0.016) animals. (F) 12,13 DiHOME treatment (n=8) increases the expression of IL1β compared with vehicle treated, PBS challenged (n=9; LME; p=0.0010) or vehicle treated, CRA challenged (n=9; LME; p=0.030) animals. (G) 12,13 DiHOME treatment 15 of CRA-challenged mice (n=18) decreases Treg frequency compared to vehicle-treated CRAchallenged mice (n=18; LME; p=0.031). (H) Peritoneal treatment with 12,13 DiHOME significantly increases the concentration of 12,13 DiHOME in the lungs (n=6; two-sided student t-test: p=0.0048) at 3 hours post-delivery. Unique symbols (p, n, u,l) represent mice from independent assays. All error bars represent the SEM. 
